VTX-2337 is a small molecule Toll-like receptor 8 (TLR8) agonist that stimulates myeloid dendritic cells, monocytes, and enhances NK cell responses. It is administered subcutaneously on a weekly basis.

VentiRx has advanced VTX-2337 into a broad clinical development program designed to evaluate the compound in multiple oncology indications in combination with a variety of anticancer agents, including chemotherapy, monoclonal antibody therapy and radiation therapy. These include a combination study with doxorubicin in late stage ovarian cancer, a combination trial with cetuximab in head and neck cancer patients and a combination trial with low-dose radiation therapy in recurrent non-Hodgkin lymphoma. A study of VTX-2337 in combination with gemcitabine in metastatic breast cancer will commence in early 2012.

For more information on the VTX-2337 clinical trial, please visit the VentiRx clinical trials page or www.clinicaltrials.gov.